Quick Answer
Milestone Pharmaceuticals Inc. reported Operating Income Loss of -$62.14 million for the year ending 2025.
- Milestone Pharmaceuticals Inc. showed a decrease of -47.6% in Operating Income Loss from 2024 to 2025.
- This data is from Milestone Pharmaceuticals Inc.'s annual report (Form 10-K), filed with the SEC on March 20, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$4.26 million | Q2 2018: -$3.68 million | Q3 2018: -$5.79 million | Q1 2019: -$10.93 million | Q2 2019: -$14.33 million | Q3 2019: -$13.73 million | Q1 2020: -$16.76 million | Q2 2020: -$13.11 million | Q3 2020: -$12.09 million | Q1 2021: -$12.59 million | Q2 2021: $712.0 thousand | Q3 2021: -$14.27 million | Q1 2022: -$14.05 million | Q2 2022: -$16.81 million | Q3 2022: -$15.03 million | Q1 2023: -$15.50 million | Q2 2023: -$16.44 million | Q3 2023: -$15.36 million | Q1 2024: -$10.48 million | Q2 2024: -$9.66 million | Q3 2024: -$9.62 million | Q1 2025: -$20.52 million | Q2 2025: -$12.53 million | Q3 2025: -$11.83 million.
- Over the full 8 years of available data (2018 to 2025), Milestone Pharmaceuticals Inc.'s Operating Income Loss has declined by 160.9%.
- Historical annual values: Fiscal year 2025: -$62.14 million | Fiscal year 2024: -$42.10 million | Fiscal year 2023: -$61.10 million | Fiscal year 2022: -$59.64 million | Fiscal year 2021: -$43.07 million | Fiscal year 2020: -$50.71 million | Fiscal year 2019: -$57.88 million | Fiscal year 2018: -$23.82 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: